Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Li-yue Sun"'
Autor:
Renjing Zhang, Yang Yang, Chunfang Hu, Mayan Huang, Wenjian Cen, Dongyi Ling, Yakang Long, Xin-Hua Yang, Boheng Xu, Junling Peng, Sujie Wang, Weijie Zhu, Mingbiao Wei, Jiaojiao Yang, Yuxia Xu, Xu Zhang, Jiangjun Ma, Fang Wang, Hongtu Zhang, Peiqing Ma, Xiaojun Zhu, Guohui Song, Li-Yue Sun, De-Shen Wang, Feng-Hua Wang, Yu-Hong Li, Sandro Santagata, Qin Li, Yan-Fen Feng, Ziming Du
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Solitary fibrous tumors (SFTs) are rare mesenchymal tumors with unpredictable evolution and with a recurrence or metastasis rate of 10-40%. Current medical treatments for relapsed SFTs remain ineffective. Here, we identify potential therapeu
Externí odkaz:
https://doaj.org/article/40b85ffd685f4b10bbdd4c6df9fa3b0a
Autor:
Li‐Yue Sun, Wen‐Jian Cen, Wen‐Ting Tang, Ya‐Kang Long, Xin‐Hua Yang, Xiao‐Meng Ji, Jiao‐Jiao Yang, Ren‐Jing Zhang, Fang Wang, Jian‐Yong Shao, Zi‐Ming Du
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6610-6617 (2021)
Abstract Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1
Externí odkaz:
https://doaj.org/article/ebef9e9e9e66427daaa7042d49c79a65
Autor:
Lu-Lu Zhang, Meng-Yao Huang, Fei-Xu, Ke-Xin Wang, Di Song, Ting Wang, Li-Yue Sun, Jian-Yong Shao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Aim: The present study aimed to evaluate the combined value of locoregional extension patterns (LEPs) and circulating cell-free Epstein–Barr virus (cf EBV) DNA for risk stratification of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) to
Externí odkaz:
https://doaj.org/article/1cab6ee08d934226b522f975260811c1
Autor:
Li-Yue Sun1, Jiao-Jiao Yang2, Xin-Xin Zeng1, Yu-Ying Jiang1,3, Ju Shen1,3, Fang Wang2 wangfang@sysucc.org.cn, Xu-Hui Zhang1 9158863@qq.com
Publikováno v:
TMR Cancer - Cancer Advances. 2023, Vol. 6, p1-10. 11p.
Autor:
Wen-Ting Tang, Xin-Hua Yang, Fang Wang, Wen-Jian Cen, Ren-Jing Zhang, Jiao-Jiao Yang, Xiao-Meng Ji, Jian Yong Shao, Ya-Kang Long, Ziming Du, Li-Yue Sun
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6610-6617 (2021)
Cancer Medicine
Cancer Medicine
Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1
Autor:
Li-Yue Sun, Wen-Jian Cen, Wen-Ting Tang, Ling Deng, Fang Wang, Xiao-Meng Ji, Jiao-Jiao Yang, Ren-Jing Zhang, Xu-Hui Zhang, Zi-Ming Du
Publikováno v:
Disease Markers, Vol 2022 (2022)
Disease Markers
Disease Markers
Background. This study was conducted to investigate the effect of alpha-fetoprotein (AFP) ratio on the prognosis of AFP-positive hepatocellular carcinoma (HCC) patients after hepatectomy. Methods. We retrospectively included 879 HCC patients with AFP
Publikováno v:
The American surgeon.
Background There is no satisfactory indicator for monitoring recurrence after resection of hepatocellular carcinoma (HCC). This retrospective study aimed to design and validate an HCC monitor recurrence (HMR) model for patients without metastasis aft
Autor:
Li-yue Sun, De-hao Yu, Liu Yang, Feng-chun Jia, Zhao-ge Juan, Yao Wang, Yan-xin Wang, Matt J. Kipper, Lin-jun Huang, Jian-guo Tang
Publikováno v:
Materials Today Communications. 33:104274
Publikováno v:
Biomarkers in Medicine. 13:1035-1044
To investigate the prevalence of EML4-ALK variants in non-small-cell lung cancer (NSCLC) patients. Materials & methods: Database of Pubmed, Embase, Medline and Cochrane Library were searched systematically to April 2018. Results: A total of 39 articl
Autor:
Jian Yong Shao, Li-Yue Sun, Yuan He, Rui Gong, Qiong Shao, Fei Xu, Zi Chen Zhang, Hai-Yun Wang, Xiao-Yun Liu
Publikováno v:
Genetic Testing and Molecular Biomarkers. 23:589-597
Objectives: Anaplastic lymphoma kinase (ALK) is one of the leading therapeutic targets in patients with non-small cell lung cancer (NSCLC). However, the clinical importance that the percentage of A...